Clarus Therapeutics went public via a SPAC merger with Blue Water Acquisition in a $379m deal.

Clarus Therapeutics, a pharmaceutical company, went public via a SPAC merger with Blue Water Acquisition, a special purposes acquisition company, in a $379m deal. “At Clarus, our goal is to develop and commercialize androgen and metabolic therapies for unmet medical conditions in men and women. My sincere thanks to our investors, employees, board of directors, and advisors for supporting our vision and making this transaction a success," Robert Dudley, Clarus President and CEO.